Cell-free DNA (cfDNA) refers to fragments of DNA that circulate freely in the bloodstream or other bodily fluids, rather than being confined within cells. These fragments are usually released into the blood when cells die and break apart, releasing their contents.

cfDNA can originate from various sources in the body, including normal cellular turnover, inflammation, tissue damage, or disease processes such as cancer. Because cfDNA carries genetic information from its source cells, its analysis has become a valuable non-invasive tool in clinical diagnostics and monitoring, particularly in fields such as oncology, prenatal screening, organ transplantation, and infectious disease¹. The presence of cfDNA was first discovered in 1948 by Paul Mandel and Pierre Métais, marking a foundational moment in molecular diagnostics.

Biological properties and sources of cell-free DNA

In the absence of disease, the majority of cfDNA is derived from regular cell turnover in tissues such as the liver, skin, and bone marrow³. In contrast, individuals with cancer may have cfDNA containing tumor-specific genetic mutations, making it a powerful tool for non-invasive cancer detection through liquid biopsies⁴. This ability to reveal tumor-related alterations is one of the most promising aspects of cfDNA analysis.

Recent studies have highlighted that, beyond tumor cells, a significant proportion of cfDNA in cancer patients originates from non-tumor sources. For instance, a study analyzing cfDNA methylation patterns found that approximately 76% of cfDNA in both cancer patients and healthy individuals is derived from leukocytes, particularly neutrophils. This suggests that systemic inflammation or immune responses contribute substantially to the cfDNA pool in cancer patients⁵.

Physical characteristics and fluctuations

cfDNA fragments typically measure around 150–200 base pairs, comparable in size to DNA wrapped around nucleosomes, making them distinct from longer genomic DNA and easily identifiable as biomarkers. Their concentration in circulation varies significantly based on physiological factors such as age, and pathological conditions like cancer, trauma, or inflammation⁸. In individuals with disease, cfDNA levels are often elevated².

cfDNA has a short half-life, ranging from about 16 minutes to a few hours, due to continuous clearance by the liver, kidneys, and immune system. Kupffer cells in the liver and macrophages in the spleen play key roles in degrading cfDNA, while the kidneys assist through filtration and enzymatic breakdown⁹.

This rapid turnover highlights the importance of timing in blood sampling for diagnostic purposes, as cfDNA levels can shift quickly in response to inflammation, injury, or disease progression, potentially affecting the accuracy of results if not appropriately timed^1,2.

Variants of cfDNA

cfDNA in circulation originates from diverse biological sources, and its characteristics can vary depending on the source cell type and physiological or pathological state. Key variants of cfDNA include:

Circulating tumor DNA (ctDNA): ctDNA is released into the bloodstream by tumor cells and contains tumor-specific genetic alterations such as point mutations, copy number variations, and epigenetic modifications. It has emerged as a powerful biomarker for liquid biopsy, enabling non-invasive cancer diagnostics, monitoring of disease progression, assessment of treatment response, and detection of minimal residual disease or emerging resistance mutations¹⁰.

Circulating cell-free fetal DNA (cffDNA): cffDNA, originating from placental trophoblasts, circulates in the maternal bloodstream during pregnancy. It is widely used in non-invasive prenatal testing (NIPT) for detecting chromosomal abnormalities such as Down syndrome, offering a safer alternative to invasive procedures like amniocentesis¹¹. This application improves prenatal care by reducing the risk to both the mother and fetus.

Donor-derived cfDNA (dd-cfDNA): dd-cfDNA refers to DNA fragments released from transplanted donor organs. In post-transplant care, elevated levels of dd-cfDNA can indicate allograft injury or rejection, providing a non-invasive method for early detection and monitoring without the need for frequent biopsies, thereby improving patient outcomes and transplant management¹².

Mitochondrial cfDNA (cf-mtDNA): cf-mtDNA originates from mitochondrial genomes and is gaining attention for its potential role in cancer detection. Elevated levels have been observed in cancers such as cholangiocarcinoma and colorectal cancer. Its distinct fragmentomic features and mitochondrial origin offer additional diagnostic value in cancer detection and tissue-of-origin classification, enhancing both the sensitivity and specificity of liquid biopsies¹³.

Exosome-associated cfDNA: Exosomes are small extracellular vesicles that carry molecular cargo, including cfDNA, from their parent cells. Exosome-associated cfDNA is protected from degradation, making it a reliable option for molecular diagnostics. These vesicles are involved in intercellular communication and tumor progression, and their cfDNA content offers insights into the physiological and pathological state of their cells of origin¹⁴.

Microbial cfDNA: Microbial cfDNA in circulation reflects the presence of microbial communities or infections in the body. Advances in sequencing have enabled detailed profiling of microbial cfDNA, which is being explored for infection monitoring and even early cancer detection, given the emerging links between microbiome composition and disease development¹⁵.

Cell-free DNA isolation and analysis techniques

The reliable analysis of cell-free DNA begins with precise and efficient extraction from biological fluids, followed by sensitive detection and characterization techniques. Given cfDNA’s fragmented nature, low abundance, and susceptibility to degradation, specialized methods have been developed to ensure its integrity and diagnostic utility.

cfDNA extraction

The critical first step in any cfDNA analysis is removing DNA from a blood sample. Given that cfDNA exists in small, fragmented forms and at low concentrations, isolating it from other blood components presents a significant challenge. To address this, various optimized techniques have been developed to efficiently extract and purify cfDNA from plasma or serum.

These methods typically include sequential steps such as centrifugation to separate plasma, filtration to remove cellular debris, and selective binding of cfDNA to specialized matrices, followed by thorough washing and elution procedures. A clear understanding of these technical processes is essential to ensure high-quality cfDNA suitable for downstream analysis.

cfDNA extraction methods

Silica membrane-based spin column extraction: Silica membrane-based spin column extraction is one of the most commonly used methods for isolating cfDNA. The process involves the binding of cfDNA to a silica membrane in the presence of chaotropic salts¹⁶. After several washing steps to remove contaminants, the purified cfDNA is eluted in a low-salt buffer. This method is user-friendly, provides consistent purity, and is ideal for low- to medium-throughput settings. However, it can be labor-intensive when processing large sample volumes and may not efficiently recover very short cfDNA fragments.

Magnetic bead-based methods: Magnetic bead-based extraction has gained popularity for its scalability and efficiency, especially in high-throughput and automated workflows. In this method, magnetic beads coated with DNA-binding surfaces selectively capture cfDNA in solution. After binding, the beads are magnetically separated, washed to remove impurities, and the cfDNA is eluted. This technique allows for higher recovery of short cfDNA fragments and is easily automated. However, it typically requires magnetic handling systems and may be more expensive compared to manual kits. Magnetic bead-based methods are most appropriate for high-throughput or automated platforms and provide improved scalability for extensive clinical studies or diagnostics^16,18.

Automated extraction systems: Automated extraction systems have become increasingly popular for isolating cell-free DNA, particularly in clinical and high-throughput research settings. These instrument-based platforms are designed to streamline the entire cfDNA isolation process, from plasma preparation to DNA elution, by using pre-programmed protocols and compatible reagent kits. They offer several advantages, including improved reproducibility, reduced hands-on time, lower contamination risk, and the ability to process multiple samples simultaneously.

Most automated systems employ magnetic bead-based technology, which is efficient in recovering short cfDNA fragments. While these systems provide consistent and scalable workflows, they do require significant upfront investment and trained personnel for operation. Nonetheless, for laboratories handling large sample volumes or requiring standardized protocols, automated extraction platforms represent a powerful tool for reliable and efficient cfDNA isolation, especially in clinical and research laboratories^16,18.

Pre-analytical variables impacting cell-free DNA quality

While cfDNA extraction is the first step in analysis, several pre-analytical factors can significantly impact sample quality. One key factor is the time between blood collection and processing. Delays can lead to cell lysis, releasing genomic DNA into the plasma and compromising the purity of cfDNA, which can hinder accurate analysis²⁰. To preserve cfDNA integrity, blood samples should ideally be processed within a few hours of collection.

Storage conditions, including temperature and handling during transport, can affect both the concentration and integrity of cfDNA. These considerations highlight the importance of rigorous standardization and control of pre-analytical procedures to ensure reliable and reproducible results²⁰.

Quantification methods for cfDNA

Once cfDNA has been extracted, accurate quantification is essential to ensure there is enough material for downstream applications. Several methods are commonly used to measure cfDNA concentration:

• UV spectrophotometry: This method estimates cfDNA concentration by measuring absorbance at 260 nm²¹. It is quick and straightforward, and instruments like traditional spectrophotometers or NanoDrop are commonly used. However, it lacks specificity and may overestimate DNA levels due to interference from RNA or proteins.
• Fluorometric assays: These assays are more sensitive and specific than UV spectrophotometry. They use double-stranded DNA-binding fluorescent dyes, providing accurate quantification even at low concentrations of cfDNA, making them particularly useful for samples with limited DNA²³.
• Digital PCR (dPCR): dPCR offers high sensitivity and precision by partitioning a sample into thousands of individual reactions to detect and quantify specific DNA sequences. It is especially valuable for identifying low-abundance cfDNA, such as circulating tumor DNA in cancer diagnostics^24,25.
• Quantitative real-time PCR (qPCR): qPCR amplifies targeted DNA sequences while simultaneously measuring their concentration using fluorescent probes. It is highly sensitive and widely used, though it requires prior knowledge of target sequences and may rely on standard curves for quantification²⁵.
• Next-generation sequencing (NGS): NGS provides a comprehensive analysis of cfDNA, enabling the detection of mutations, copy number variations, and other genomic alterations²⁵. While extremely informative, NGS is complex, costly, and typically reserved for applications requiring deep genomic insights.
• Capillary electrophoresis: This technique separates DNA fragments by size, offering both qualitative and quantitative insights into cfDNA integrity and size distribution. Although useful for fragment analysis, it may not detect contaminants that could interfere with downstream enzymatic reactions²⁵.

Analytical technologies for cell-free DNA

Once cfDNA is isolated and quantified, the next step is to analyze its content. Various cutting-edge technologies allow researchers to explore the genetic, epigenetic, and structural features of cfDNA in detail.

High-throughput sequencing

Next-generation sequencing has revolutionized cfDNA analysis by enabling the parallel sequencing of millions of DNA fragments, providing a comprehensive view of cfDNA’s genetic landscape²⁴. In oncology, NGS is instrumental in identifying mutations, gene fusions, and other genomic alterations within ctDNA.

Beyond genetic changes, NGS also facilitates the analysis of epigenetic markers, such as DNA methylation patterns, that can signal disease progression or treatment response. One of the key advantages of NGS is its exceptional sensitivity, allowing for the detection of rare mutations, making it a powerful tool for early cancer detection and ongoing disease monitoring.

Digital PCR and droplet digital PCR (dPCR)

Digital PCR (dPCR) offers another powerful tool for cfDNA analysis. Unlike traditional PCR, which amplifies a bulk DNA sample, dPCR partitions the sample into many tiny droplets or wells, allowing for the precise counting of target DNA molecules. This method enhances sensitivity, making it ideal for detecting low-abundance cfDNA, such as ctDNA, in early-stage cancers²⁴.

Droplet digital PCR (ddPCR) goes one step further by utilizing water-in-oil emulsions, elevating accuracy and offering absolute DNA target quantification²⁶. While dPCR offers higher sensitivity than NGS for specific applications, its throughput is generally lower, making it more suited for targeted analysis of specific regions of the genome.

Nanopore sequencing for cfDNA analysis

Nanopore sequencing, a cutting-edge technology, enables real-time, direct DNA sequencing without the need for amplification or chemical modification. It is valuably contributing to the analysis of cell-free DNA due to its ability to read long DNA fragments and detect epigenetic modifications like methylation directly²⁷.

This platform can reveal structural variations, fragmentation patterns, and even the tissue of origin, making it a powerful tool for liquid biopsy applications. Its portability and rapid turnaround time further enhance its clinical potential, especially for early cancer detection, treatment monitoring, and personalized medicine²⁷.

Emerging techniques in cfDNA analysis

As cfDNA research continues to advance, a few new techniques, such as methylation profiling, copy number variation detection, epigenetic analysis, and fragmentomics, are becoming increasingly popular.

• DNA methylation alterations may be predictive of diseases such as cancer, and cfDNA offers a non-invasive means of tracking these alterations. Methylation profiling of cfDNA is being developed as a potential diagnostic method for the detection of early cancers since tumors tend to have unique methylation signatures relative to normal tissues²⁸.
• Copy number variation (CNV) defined as alterations in the copy number of a specific DNA segment, can be detected in cfDNA. It is particularly significant in cancer research because numerous cancers show CNVs that are responsible for oncogenesis. Detection of CNVs in cfDNA can be useful to identify particular tumor features and track disease progression^28,29.
• Epigenetic modifications, such as histone or non-coding RNA regulation, are an additional level of information that cfDNA can provide³⁰. Fragmentomics, which examines the size distribution and properties of cfDNA fragments, can provide insights into the fragmentation of DNA during apoptosis or necrosis. Combined, these epigenetic and fragmentomic methods provide an additional dimension to cfDNA analysis, increasing its utility for the diagnosis and monitoring of a broad spectrum of conditions.
• Apart from these traditional, established techniques, recent advancements have introduced several emerging techniques, such as multimodal cfDNA profiling, nucleosome footprinting, chromatin accessibility, and machine learning integration, that enhance the analytical capabilities of cell-free DNA.
• Recent advancements have led to the development of multimodal cfDNA profiling platforms that simultaneously assess whole-genome methylation, copy number variations (CNVs), and fragmentomic patterns within a single assay. By combining multiple cfDNA characteristics in one analysis, this integrated approach markedly improves the sensitivity and specificity of cancer detection³¹.
• Techniques such as EPIC-Seq enable the analysis of cfDNA nucleosome positioning and fragment size distribution, offering insights into transcriptional regulation and chromatin accessibility³⁰. These patterns can be used to infer the tissue of origin and gene expression activity, adding a layer of functional information to cfDNA analysis.
• Machine learning models are increasingly being applied to cfDNA datasets to integrate diverse features like methylation profiles, CNVs, and fragmentation patterns. These algorithms can uncover complex, non-linear relationships within the data, thereby improving the precision of cancer classification and early detection³².

Medical applications of cell-free DNA

Cell-free DNA has emerged as a transformative tool in various areas of clinical medicine due to its non-invasive nature and ability to reflect physiological and pathological states.

Cancer diagnostics and monitoring

In oncology, cfDNA, particularly circulating tumor DNA, is used for early cancer detection, monitoring treatment response, identifying resistance mutations, and tracking minimal residual disease through liquid biopsy.

Circulating tumor DNA in liquid biopsy: ctDNA contains specific mutations and modifications that are characteristic of cancer cells, making it a valuable tool for "liquid biopsy"^32,33. This non-invasive approach allows for the detection of mutations, gene fusions, and copy number alterations, providing insights into the genetic makeup of tumors without the need for a traditional tissue biopsy. In 1965, Bendidch et al. showed that cfDNA derived from neoplastic cells could be involved in metastases. Almost ten years later, it was demonstrated by the radioimmunoassay technique that half of the cancer patients had significantly higher levels of cfDNA compared to controls³⁵.

Liquid biopsies using ctDNA are rapidly transforming cancer medicine. They offer a real-time method to monitor tumor evolution, assess how a cancer responds to treatment, and detect minimal residual disease - small numbers of cancer cells that may remain after treatment and potentially lead to recurrence. ctDNA can also identify mutations that inform personalized treatment strategies, including the use of targeted therapies or immunotherapy. As research advances, new cfDNA biomarkers for cancer are being discovered, further enhancing the potential of ctDNA in personalized cancer care.

Novel cfDNA biomarkers for cancer: In addition to ctDNA, scientists are exploring other cfDNA biomarkers to enhance cancer detection and monitoring^33,34. These include DNA methylation pattern changes, copy number alterations, and fragment size distributions that can be associated with certain types of cancer.

For example, cancer-specific methylation signatures in cfDNA can help detect cancers at an earlier stage or identify aggressive forms of cancer. As the field evolves, novel cfDNA biomarkers are expected to expand the clinical utility of liquid biopsies, enhancing early detection, monitoring therapy, and even predicting cancer recurrence.

Prenatal screening and diagnostics

Cell-free fetal DNA (cffDNA) in non-invasive prenatal testing (NIPT): Cell-free fetal DNA is a key application of cell-free DNA in prenatal care³³. During pregnancy, small fragments of fetal DNA cross into the maternal bloodstream, where they can be analyzed to assess fetal health. NIPT uses cffDNA to screen for genetic conditions such as Down syndrome (trisomy 21), trisomy 18, and trisomy 13¹¹. A study has reported that NIPT has a detection rate of over 99% for trisomy 21 and 13, with a false-positive rate of less than 0.1%¹¹.

NIPT is highly accurate and offers a safer alternative to invasive procedures like amniocentesis, which carries a small risk of miscarriage. NIPT has revolutionized prenatal screening by providing expectant parents with an early, non-invasive option that boasts high sensitivity and specificity. This method has significantly reduced the need for invasive tests, giving both physicians and patients greater confidence in the results and minimizing unnecessary risks.

Interpretation of cfDNA screening results: While NIPT using cfDNA is highly accurate, interpreting the results still requires careful consideration. False positives, though rare, can occur, and not all positive results indicate the presence of a genetic condition. Some results may be inconclusive, particularly in cases where cfDNA is present in low quantities or if there are technical issues during testing. Genetic counseling is essential to help interpret results and guide expectant parents in decision-making, ensuring they have a complete understanding of the test’s implications.

Organ transplant monitoring

Another significant application of cfDNA is in the monitoring of organ transplant recipients. After a transplant, donor-derived cfDNA (dd-cfDNA) circulates in the recipient’s bloodstream, and its levels can be indicative of transplant rejection⁷. Monitoring dd-cfDNA offers a non-invasive alternative to biopsy for detecting early signs of organ rejection, reducing the need for invasive procedures that carry risks and are often uncomfortable for patients.

By analyzing dd-cfDNA, clinicians can detect rejection events before they become clinically significant. This allows for timely intervention and adjustments to immunosuppressive therapy, which can improve long-term outcomes for transplant patients and reduce the likelihood of graft failure.

Emerging clinical applications

Infectious disease diagnostics: Infectious disease is another field where cfDNA is proving to be promising^36,37. When the body is infected with pathogens like bacteria, viruses, or fungi, they can spill DNA into the blood. Testing cfDNA from these sources can identify infections without invasive testing.

This is especially helpful for diagnosing infection in immunocompromised individuals, such as chemotherapy or organ transplants, or COVID-19 patients, where conventional diagnostic techniques may not work as well. For example, a recently developed approach called mNGS assists in identifying infections in sepsis patients by cfDNA sequencing, allowing for quick and precise diagnosis without the use of culture-based techniques³⁸.

In addition, diagnostics based on cfDNA can identify a broader range of infections compared to conventional diagnostic methods, which tend to address a single causative agent. This broad-spectrum capability would result in the faster and more accurate identification of infectious diseases, mainly when the pathogens are difficult to identify with cultures or imaging.

Assessment of autoimmune disease: Autoimmune diseases arise when the body’s immune system erroneously attacks its healthy tissues, leading to chronic inflammation and tissue damage^33,36. These conditions can be challenging to diagnose and monitor, but cfDNA is offering new insights. In autoimmune diseases, cell death and the release of DNA fragments can increase, and analyzing cfDNA levels or specific genetic alterations can help diagnose conditions like lupus or rheumatoid arthritis.

For instance, it is highlighted that cfDNA levels in SLE patients correlate with disease flares and can serve as a marker of immune activation and tissue damage, offering the potential for real-time disease monitoring³⁹.

Furthermore, cfDNA analysis may help in monitoring disease activity and treatment response, providing a more dynamic and comprehensive view of the patient’s condition than conventional methods. This is an area of ongoing research, and as more is learned, cfDNA could become a routine tool in the management of autoimmune diseases.

Role in monitoring neurodegenerative disease: The potential of cfDNA in the diagnosis of neurodegenerative conditions like Alzheimer’s and Parkinson’s disease is an active and emerging field of research⁴⁰. In neurodegenerative disease, cells within the brain become injured and may release fragments of cfDNA into the bloodstream and cerebrospinal fluid. Although mechanisms are not fully understood, preliminary findings indicate that cfDNA may act as a biomarker to follow the course of disease or the effectiveness of treatment.

The potential to detect cfDNA from the central nervous system (CNS) in peripheral blood samples is groundbreaking. This could allow for earlier diagnosis and better management of neurodegenerative diseases, where current diagnostic methods rely heavily on imaging and clinical symptoms, which often appear in the later stages of the disease.

Challenges and considerations in cfDNA research

Despite cell-free DNA's potential, researchers and clinicians face several challenges. Understanding these challenges is key to advancing the clinical utility of cfDNA-based diagnostics.

Detecting low-abundance cfDNA, especially tumor-derived ctDNA, remains a key challenge due to its minimal presence amid abundant normal cfDNA. Highly sensitive methods like NGS and digital PCR are essential but still face limitations in consistency across patients. As cfDNA testing grows, standardizing protocols, from extraction to analysis, is vital for reliable results^29,41. Additionally, high costs and infrastructure demands pose barriers to widespread adoption, especially in resource-limited settings.

Ethical and regulatory issues

Non-invasive prenatal testing using cfDNA raises ethical concerns, particularly regarding selective pregnancy termination and the anxiety caused by uncertain or false-positive results⁴². These issues underscore the need for thorough counseling and informed decision-making. As cfDNA diagnostics expand, evolving regulatory frameworks must ensure accurate, ethical, and responsible use through clear guidelines and strong oversight.

Future directions in cell-free DNA research

cfDNA research is rapidly advancing, with new technologies and applications continuously pushing the boundaries of diagnostics and disease monitoring. As our understanding of cfDNA deepens, so does its potential to transform healthcare.

A major area of innovation is the development of more efficient and accurate methods for cfDNA isolation and analysis⁴³. Technologies are being refined to handle even trace amounts of cfDNA, particularly in liquid biopsies for cancer, where circulating tumor DNA is often present at low concentrations. Advancements such as enhanced magnetic bead-based systems and automated workflows are improving both the speed and quality of cfDNA extraction, making diagnostics more practical and accessible for routine clinical use.

Machine learning (ML) is also playing an increasingly important role in cfDNA research^34,41. By applying ML algorithms, researchers can uncover patterns and correlations in cfDNA data that may not be detectable with traditional methods. These insights can aid in predicting disease progression, treatment response, and even early detection of conditions like cancer. As ML techniques evolve, they promise greater accuracy and more personalized treatment strategies.

cfDNA holds great promise for early disease detection. As technologies advance, cfDNA-based tests could identify diseases such as cancer or neurological disorders at much earlier, and more treatable, stages. Early detection improves outcomes and opens the door to preventative interventions that can save lives and reduce healthcare costs.

Additionally, cfDNA could revolutionize personalized medicine by offering a minimally invasive way to monitor disease progression and treatment efficacy^34,44. Instead of relying on traditional biopsies, cfDNA-based diagnostics can provide real-time insights, enabling faster adjustments to therapy. This paves the way for more tailored treatments with fewer side effects and better outcomes.

FAQs

How is cell-free DNA isolated from blood?

Cell-free DNA (cfDNA) is isolated from blood using several methods. Common techniques include centrifugation to separate plasma, followed by extraction using silica membrane columns or magnetic beads. These methods help remove cellular debris and contaminants, allowing for the purification of cfDNA. Magnetic bead-based methods are often faster and more cost-effective, while silica membrane methods can provide higher yields, depending on the specific application and required purity.

How does a cell-free DNA test work for prenatal screening?

Cell-free DNA (cfDNA) prenatal screening involves analyzing fetal DNA fragments in a pregnant woman’s blood. These fragments, which circulate from the placenta, are tested for chromosomal abnormalities like Down syndrome. The test is non-invasive, typically performed after 10 weeks of pregnancy, and offers high sensitivity for detecting certain conditions. However, it is not definitive and requires follow-up diagnostic tests for confirmation.

What are the limitations of cell-free DNA testing in cancer detection?

Cell-free DNA (cfDNA) testing for cancer detection faces several limitations. The low concentration and fragmented nature of cfDNA make analysis challenging. Additionally, distinguishing tumor-derived DNA from normal cell DNA can be difficult, especially in early-stage cancers where tumor DNA is scarce. Methodological and pre-analytical factors also affect the clinical sensitivity of cfDNA-based diagnostics, requiring advanced sequencing techniques to overcome these hurdles.

References

1.       Korabecna, M., Zinkova, A., Brynychova, I., et al., Cell-free DNA in plasma as an essential immune system regulator. Scientific reports, 10(1), 17478 (2020).

2.      Grabuschnig, S., Bronkhorst, A. J., Holdenrieder, S., et al., Putative origins of cell-free DNA in humans: a review of active and passive nucleic acid release mechanisms. International journal of molecular sciences, 21(21), 8062 (2020).

3.      Mouliere, F. A hitchhiker’s guide to cell-free DNA biology. Neuro-oncology advances, 4(Supplement_2), ii6-ii14 (2022).

4.      Cisneros-Villanueva, M., Hidalgo-Pérez, L., Rios-Romero, M., et al., Cell-free DNA analysis in current cancer clinical trials: a review. British journal of cancer, 126(3), 391-400 (2022).

5.      Mattox, A. K., Douville, C., Wang, Y., et al. The origin of highly elevated cell-free DNA in healthy individuals and patients with pancreatic, colorectal, lung, or ovarian cancer. Cancer discovery, 13(10), 2166-2179 (2023).

6.      Sebastian, A., Silvy, M., Coiffard, B., et al. A review of cell-free DNA and epigenetics for non-invasive diagnosis in solid organ transplantation. Frontiers in Transplantation, 3, 1474920 (2024).

7.      de Miranda, F. S., Barauna, V. G., Dos Santos, L., et al. Properties and application of cell-free DNA as a clinical biomarker. International journal of molecular sciences, 22(17), 9110 (2021).

8.      Saelee, S. L., Lovejoy, A. F., Hinzmann, B., et al., Quantitative PCR–based method to assess cell-free DNA quality, adjust input mass, and improve next-generation sequencing assay performance. The Journal of Molecular Diagnostics, 24(6), 566-575 (2022).

9.      Kustanovich, A., Schwartz, R., Peretz, T., et al. Life and death of circulating cell-free DNA. Cancer biology & therapy, 20(8), 1057-1067 (2019).

10.  Bittla, P., Kaur, S., Sojitra, V., et al., Exploring circulating tumor DNA (CtDNA) and its role in early detection of cancer: A systematic review. Cureus, 15(9) (2023).

11.  Rafi, I., Hill, M., Hayward, J., & Chitty, L. S. Non-invasive prenatal testing: use of cell-free fetal DNA in Down syndrome screening. British Journal of General Practice, 67(660), 298-299 (2017).

12.  Akifova, A., Budde, K., Oellerich, M., et al., Perspective for Donor-Derived Cell-Free DNA in Antibody-Mediated Rejection After Kidney Transplantation: Defining Context of Use and Clinical Implications. Transplant International, 37, 13239 (2024).

13.  Liu, Y., Peng, F., Wang, S., et al. Aberrant fragmentomic features of circulating cell-free mitochondrial DNA as novel biomarkers for multi-cancer detection. EMBO Molecular Medicine, 16(12), 3169-3183 (2024).

14.  Yu, D., Li, Y., Wang, M., et al. Exosomes as a new frontier of cancer liquid biopsy. Molecular cancer, 21(1), 56 (2022).

15.  Kataria, R., Shoaie, S., Grigoriadis, A., et al. Leveraging circulating microbial DNA for early cancer detection. Trends in Cancer, 9(11), 879-882 (2023).

16.  Polatoglou, E., Mayer, Z., Ungerer, V., et al., Isolation and quantification of plasma cell-free DNA using different manual and automated methods. Diagnostics, 12(10), 2550 (2022).

17.  Gautam, A. Spin Column-Based Isolation of Nucleic Acid. In  DNA and RNA Isolation Techniques for Non-Experts  (pp. 47-53). Cham: Springer International Publishing (2022).

18.  Bronkhorst, A. J., Ungerer, V., & Holdenrieder, S., Comparison of methods for the isolation of cell-free DNA from cell culture supernatant. Tumor Biology, 42(4), 1010428320916314 (2020).

19.  Magnetic Beads (microRNA & Oligo Purification) - BioDynami

20.  Trigg, R. M., Martinson, L. J., Parpart-Li, S., et al., Factors that influence quality and yield of circulating-free DNA: A systematic review of the methodology literature. Heliyon, 4(7) (2018).

21.  Pedini, P., Graiet, H., Laget, L., et al., Qualitative and quantitative comparison of cell-free DNA and cell-free fetal DNA isolation by four (semi-) automated extraction methods: impact in two clinical applications: chimerism quantification and noninvasive prenatal diagnosis. Journal of translational medicine, 19, 1-11 (2021).

22.  Dash, H. R., Shrivastava, P., Das, S., et al. Quantification of DNA by Using UV–Visible Spectrophotometer. Principles and Practices of DNA Analysis: A Laboratory Manual for Forensic DNA Typing, 127-132 (2020).

23.  Marcatti, M., Saada, J., Okereke, I., et al. Quantification of circulating cell free mitochondrial DNA in extracellular vesicles with picoGreen™ in liquid biopsies: fast assessment of disease/trauma severity. Cells, 10(4), 819 (2021).

24.  Kueng, N., Arcioni, S., Sandberg, F., et al. Comparison of methods for donor-derived cell-free DNA quantification in plasma and urine from solid organ transplant recipients. Frontiers in genetics, 14, 1089830 (2023).

25.  Bohers, E., Viailly, P. J., & Jardin, F. cfDNA sequencing: technological approaches and bioinformatic issues. Pharmaceuticals, 14(6), 596 (2021).

26.  Gezer, U., Bronkhorst, A. J., & Holdenrieder, S. The clinical utility of droplet digital PCR for profiling circulating tumor DNA in breast cancer patients. Diagnostics, 12(12), 3042 (2022).

27.  Si, H. Q., Wang, P., Long, F., et al. Cancer liquid biopsies by Oxford Nanopore Technologies sequencing of cell-free DNA: from basic research to clinical applications. Molecular Cancer, 23(1), 265 (2024).

28.   Volik, S., Alcaide, M., Morin, R. D., et al., Cell-free DNA (cfDNA): clinical significance and utility in cancer shaped by emerging technologies. Molecular Cancer Research, 14(10), 898-908 (2016).

29.  Song, P., Wu, L. R., Yan, Y. H et al. Limitations and opportunities of technologies for the analysis of cell-free DNA in cancer diagnostics. Nature biomedical engineering, 6**(**3), 232-245 (2022).

30.  Esfahani, M.S., Hamilton, E.G., Mehrmohamadi, M.  et al.  Inferring gene expression from cell-free DNA fragmentation profiles.  Nat Biotechnol  40, 585–597 (2022).

31.  Kim, S.Y., Jeong, S., Lee, W.  et al.  Cancer signature ensemble integrating cfDNA methylation, copy number, and fragmentation facilitates multi-cancer early detection.  Exp Mol Med  55, 2445–2460 (2023).

32.  Moser, T., Kühberger, S., Lazzeri, I., et al. Bridging biological cfDNA features and machine learning approaches. Trends in Genetics, 39(4), 285-307 (2023).

33.  Ranucci, R. Cell-free DNA: applications in different diseases. In Cell-free DNA as diagnostic markers: methods and protocols (pp. 3-12). New York, NY: Springer New York (2018).

34.  Yan, Y. Y., Guo, Q. R., Wang, F. H., et al., Cell-free DNA: hope and potential application in cancer. Frontiers in cell and developmental biology, 9, 639233 (2021).

35.  Bendich, A., Wilczok, T., & Borenfreund, E. Circulating DNA as a possible factor in oncogenesis. Science, 148(3668), 374-376 (1965).

36.  Hovhannisyan, G., Harutyunyan, T., Aroutiounian, R. et al., The diagnostic, prognostic, and therapeutic potential of cell-free DNA with a special focus on COVID-19 and other viral infections. International journal of molecular sciences, 24(18), 14163 (2023).

37.  Roberts, R. The Basics and Applications of Cell-Free DNA (2023).

38.  Hu, Y., Zhao, Y., Zhang, Y et al. Cell-free DNA: a promising biomarker in infectious diseases. Trends in Microbiology (2024).

39.  Mondelo-Macía, P., Castro-Santos, P., Castillo-García, A., et al. Circulating free DNA and its emerging role in autoimmune diseases. Journal of personalized medicine, 11(2), 151 (2021).

40.  Pollard, C., Aston, K., Emery, B. R., Hill, J., & Jenkins, T. Detection of neuron-derived cfDNA in blood plasma: A new diagnostic approach for neurodegenerative conditions. Frontiers in Neurology, 14, 1272960 (2023).

41.  Bronkhorst, A. J., Ungerer, V., Oberhofer, A., et al., New perspectives on the importance of cell-free DNA biology. Diagnostics, 12(9), 2147 (2022).

42.  Grace, M. R., Hardisty, E., Dotters-Katz., et al., Cell-free DNA screening: complexities and challenges of clinical implementation. Obstetrical & gynecological survey, 71(8), 477-487 (2016).

43.  Stawski, R., Stec-Martyna, E., Chmielecki, A., et al., Current trends in cell-free DNA applications. scoping review of clinical trials. Biology, 10(9), 906 (2021).

44.  Telekes, A., & Horváth, A. The role of cell-free DNA in cancer treatment decision making. Cancers, 14(24), 6115 (2022).